4Moving Biotech receives US FDA’s IND clearance for 4P004; strengthens its position as a leading innovator in disease-modifying osteoarthritis therapeutics

4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), announced that the US Food and Drug Administration (FDA) has

To access the full article, please log in or subscribe.